Oral contraceptives, hormone therapy and cardiovascular risk

Climacteric

Volumn 11, Issue 5, 2008, Pages 355-363

  Shapiro, S ^a,b,c  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cardiovascular risk; Hormone therapy; Oral contraceptives

Indexed keywords

BLOOD CLOTTING FACTOR 5; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; DOPPLER ECHOGRAPHY; DRUG CLASSIFICATION; DRUG USE; ESTROGEN THERAPY; FOLLOW UP; GENETIC PREDISPOSITION; HEART INFARCTION; HORMONAL THERAPY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; OBSERVATIONAL STUDY; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

CONTRACEPTIVES, ORAL, COMBINED; CORONARY DISEASE; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; STROKE; VENOUS THROMBOEMBOLISM;

EID: 51649087160     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802322848     Document Type: Article

References (29)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
3. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
4. Manson JE, Hsia HJ, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-4
5. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589-99
6. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
7. Manson JE, Bassuk SS. Invited commentary: Hormone therapy and risk of coronary heart disease - why renew the focus on the early years of the menopause? Am J Epidemiol 2007;166:511-17
8. Royal College of General Practitioners. Oral contraceptives, venous thromboembolism, and varicose veins. Royal College of General Practitioners Oral Contraception Study. J R Coll Gen Pract 1978;28:393-9
9. Farmer RD, Lawrenson RA, Todd J, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000;49:580-90
10. Farley TM, Meirik O, Marmot MG, Chang CL, Poulter NR. Oral contraceptives and the risk of venous thromboembolism: impact of duration of use. Contraception 1998;57:61-5
11. Suissa S, Spitzer WO. Oral contraceptives and the risk of venous thromboembolism: impact of duration of use. Contraception 1998;57:64-5
12. Ridker PM, Mileticj JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2
13. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8
14. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO, and the Transnational Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996;54:5-13
15. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999;14:1493-9
16. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6
17. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen only contraceptives and cardiovascular risk: results of the Transnational Study on Oral Contraceptives and Health of Young Women. Eur J Contracept Reprod Health Care 1999;4:67-73
18. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6
19. Farley TMM, Meirik O, Chang CL, et al. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-8
20. Jick H, Jick S, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progastagen components. Lancet 1995;346:1589-93
21. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD and the Transnational Research Group. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-8
22. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:131-4
23. Lewis MA, Spitzer WO. Risk of oral contraceptives and recency of market introduction. Contraception 1997;55:192-4
24. Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996;312:88-90
25. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000;15:817-21
26. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939-45
27. Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol 1997;50:223-9
28. Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;6:302-10
29. Nelson HD, Humphrey LN, Nygren P, Allan JA. Postmenopausal hormone replacement therapy. Scientific review. JAMA 2002;288:872-82